Metabolomic profiling reveals salivary hypotaurine as a potential early detection marker for medication-related osteonecrosis of the jaw

Wakako Yatsuoka, Takao Ueno, Kanako Miyano, Yasuhito Uezono, Ayame Enomoto, Miku Kaneko, Sana Ota, Tomoyoshi Soga, Masahiro Sugimoto, Toshikazu Ushijima

Research output: Contribution to journalArticle

Abstract

Medication-related osteonecrosis of the jaw (MRONJ) is a rare but serious adverse event of bone-modifying agents used to prevent bone complications in cancer patients with bone metastasis. Currently, early treatment is the only way to prevent further progression, as the pathogenesis of MRONJ has not yet been elucidated, and a standard treatment has not been established. The aim of this study was to identify a marker for early detection marker of MRONJ by exploring substances in saliva specific to MRONJ at an early stage. We collected salivary samples from 17 patients with MRONJ and conducted metabolomic analyses using capillary electrophoresis mass spectrometry for non-targeted analysis of hydrophilic metabolites. In the screening cohort, we compared the saliva of patients with stage ≥1 advanced MRONJ (n = 9) with that of controls without MRONJ before chemotherapy (n = 9). The top 5 most elevated salivary metabolites were histamine, 3-(4-hydroxyphenyl)propionate, malonate, carnosine, and hypotaurine. In the validation cohort, we analyzed additional patients with stage ≥1 advanced MRONJ (n = 8) and controls without MRONJ after chemotherapy (n = 9), confirming a significant 2.28-fold elevation in the salivary concentration of hypotaurine. These results revealed elevated salivary hypotaurine concentration as a potential marker for the early detection of MRONJ.

Original languageEnglish
Article numbere0220712
JournalPloS one
Volume14
Issue number8
DOIs
Publication statusPublished - 2019 Jan 1

Fingerprint

Metabolomics
Osteonecrosis
metabolomics
Jaw
jaws
drug therapy
Bone
Chemotherapy
Metabolites
Carnosine
Capillary electrophoresis
Propionates
Histamine
Mass spectrometry
Screening
Saliva
Bone and Bones
bones
saliva
hypotaurine

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)
  • Agricultural and Biological Sciences(all)

Cite this

Metabolomic profiling reveals salivary hypotaurine as a potential early detection marker for medication-related osteonecrosis of the jaw. / Yatsuoka, Wakako; Ueno, Takao; Miyano, Kanako; Uezono, Yasuhito; Enomoto, Ayame; Kaneko, Miku; Ota, Sana; Soga, Tomoyoshi; Sugimoto, Masahiro; Ushijima, Toshikazu.

In: PloS one, Vol. 14, No. 8, e0220712, 01.01.2019.

Research output: Contribution to journalArticle

Yatsuoka, W, Ueno, T, Miyano, K, Uezono, Y, Enomoto, A, Kaneko, M, Ota, S, Soga, T, Sugimoto, M & Ushijima, T 2019, 'Metabolomic profiling reveals salivary hypotaurine as a potential early detection marker for medication-related osteonecrosis of the jaw', PloS one, vol. 14, no. 8, e0220712. https://doi.org/10.1371/journal.pone.0220712
Yatsuoka, Wakako ; Ueno, Takao ; Miyano, Kanako ; Uezono, Yasuhito ; Enomoto, Ayame ; Kaneko, Miku ; Ota, Sana ; Soga, Tomoyoshi ; Sugimoto, Masahiro ; Ushijima, Toshikazu. / Metabolomic profiling reveals salivary hypotaurine as a potential early detection marker for medication-related osteonecrosis of the jaw. In: PloS one. 2019 ; Vol. 14, No. 8.
@article{ea17b699df21464cbc9c38f505e5a0f8,
title = "Metabolomic profiling reveals salivary hypotaurine as a potential early detection marker for medication-related osteonecrosis of the jaw",
abstract = "Medication-related osteonecrosis of the jaw (MRONJ) is a rare but serious adverse event of bone-modifying agents used to prevent bone complications in cancer patients with bone metastasis. Currently, early treatment is the only way to prevent further progression, as the pathogenesis of MRONJ has not yet been elucidated, and a standard treatment has not been established. The aim of this study was to identify a marker for early detection marker of MRONJ by exploring substances in saliva specific to MRONJ at an early stage. We collected salivary samples from 17 patients with MRONJ and conducted metabolomic analyses using capillary electrophoresis mass spectrometry for non-targeted analysis of hydrophilic metabolites. In the screening cohort, we compared the saliva of patients with stage ≥1 advanced MRONJ (n = 9) with that of controls without MRONJ before chemotherapy (n = 9). The top 5 most elevated salivary metabolites were histamine, 3-(4-hydroxyphenyl)propionate, malonate, carnosine, and hypotaurine. In the validation cohort, we analyzed additional patients with stage ≥1 advanced MRONJ (n = 8) and controls without MRONJ after chemotherapy (n = 9), confirming a significant 2.28-fold elevation in the salivary concentration of hypotaurine. These results revealed elevated salivary hypotaurine concentration as a potential marker for the early detection of MRONJ.",
author = "Wakako Yatsuoka and Takao Ueno and Kanako Miyano and Yasuhito Uezono and Ayame Enomoto and Miku Kaneko and Sana Ota and Tomoyoshi Soga and Masahiro Sugimoto and Toshikazu Ushijima",
year = "2019",
month = "1",
day = "1",
doi = "10.1371/journal.pone.0220712",
language = "English",
volume = "14",
journal = "PLoS One",
issn = "1932-6203",
publisher = "Public Library of Science",
number = "8",

}

TY - JOUR

T1 - Metabolomic profiling reveals salivary hypotaurine as a potential early detection marker for medication-related osteonecrosis of the jaw

AU - Yatsuoka, Wakako

AU - Ueno, Takao

AU - Miyano, Kanako

AU - Uezono, Yasuhito

AU - Enomoto, Ayame

AU - Kaneko, Miku

AU - Ota, Sana

AU - Soga, Tomoyoshi

AU - Sugimoto, Masahiro

AU - Ushijima, Toshikazu

PY - 2019/1/1

Y1 - 2019/1/1

N2 - Medication-related osteonecrosis of the jaw (MRONJ) is a rare but serious adverse event of bone-modifying agents used to prevent bone complications in cancer patients with bone metastasis. Currently, early treatment is the only way to prevent further progression, as the pathogenesis of MRONJ has not yet been elucidated, and a standard treatment has not been established. The aim of this study was to identify a marker for early detection marker of MRONJ by exploring substances in saliva specific to MRONJ at an early stage. We collected salivary samples from 17 patients with MRONJ and conducted metabolomic analyses using capillary electrophoresis mass spectrometry for non-targeted analysis of hydrophilic metabolites. In the screening cohort, we compared the saliva of patients with stage ≥1 advanced MRONJ (n = 9) with that of controls without MRONJ before chemotherapy (n = 9). The top 5 most elevated salivary metabolites were histamine, 3-(4-hydroxyphenyl)propionate, malonate, carnosine, and hypotaurine. In the validation cohort, we analyzed additional patients with stage ≥1 advanced MRONJ (n = 8) and controls without MRONJ after chemotherapy (n = 9), confirming a significant 2.28-fold elevation in the salivary concentration of hypotaurine. These results revealed elevated salivary hypotaurine concentration as a potential marker for the early detection of MRONJ.

AB - Medication-related osteonecrosis of the jaw (MRONJ) is a rare but serious adverse event of bone-modifying agents used to prevent bone complications in cancer patients with bone metastasis. Currently, early treatment is the only way to prevent further progression, as the pathogenesis of MRONJ has not yet been elucidated, and a standard treatment has not been established. The aim of this study was to identify a marker for early detection marker of MRONJ by exploring substances in saliva specific to MRONJ at an early stage. We collected salivary samples from 17 patients with MRONJ and conducted metabolomic analyses using capillary electrophoresis mass spectrometry for non-targeted analysis of hydrophilic metabolites. In the screening cohort, we compared the saliva of patients with stage ≥1 advanced MRONJ (n = 9) with that of controls without MRONJ before chemotherapy (n = 9). The top 5 most elevated salivary metabolites were histamine, 3-(4-hydroxyphenyl)propionate, malonate, carnosine, and hypotaurine. In the validation cohort, we analyzed additional patients with stage ≥1 advanced MRONJ (n = 8) and controls without MRONJ after chemotherapy (n = 9), confirming a significant 2.28-fold elevation in the salivary concentration of hypotaurine. These results revealed elevated salivary hypotaurine concentration as a potential marker for the early detection of MRONJ.

UR - http://www.scopus.com/inward/record.url?scp=85070664141&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85070664141&partnerID=8YFLogxK

U2 - 10.1371/journal.pone.0220712

DO - 10.1371/journal.pone.0220712

M3 - Article

AN - SCOPUS:85070664141

VL - 14

JO - PLoS One

JF - PLoS One

SN - 1932-6203

IS - 8

M1 - e0220712

ER -